Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NewGam high-infusion-rate extension study in primary immunodeficiency
ISRCTN11002924Phase 3Completed
- Sponsor
- Octapharma
- Start
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of subcuvia in Immunogenetic disorder, sponsored by Octapharma. Primary endpoints: Occurrence of adverse events, Occurrence of temporally associated adverse events and 4 more. Started Mar 2011; status: completed.
02
Drugs
subcuvia
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on ISRCTN11002924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11002924.